| Class | Thiazide |
|---|---|
| Chemistry |
Thiazides are benzothiadiazines, modified sulfanilamides which still have some carbonic anhydrase activity; related functionally to "thiazide-like" diuretics (eg. indapamide, chlorthalidone, metolazone).
|
| Routes of administration |
Oral - though the only strictly oral thiazides seem to be the ones available in Australia (hydrochlorothiazide and indapamide), whereas the unobtainable chlorothiazide and metolazone can be given intravenously. |
| Absorption |
Oral bioavailability of hydrochlorothiazide is 65-75%, which is roughly representative of its class.
|
| Solubility |
For hydrochlorothiazide, pKa 9.09; it is practically insoluble in water. So is indapamide (pKa 8.8)
|
| Distribution |
Modest VODs = 1.5-4.2L/kg for hydrochlorothiazide and 0.4-1.0L/kg for indapamide.
|
| Metabolism |
Hydrochlorothiazide not undergo any hepatic metabolism, but indapamide does.
|
| Elimination |
Hydrochlorothiazide is eliminated renally (half life is 6-9 hours), whereas indapamide is almost entirely excreted by the liver; and metolazone is eliminated in the bile, enterohepatically recirculated, and then eliminated in the urine.
|
| Time course of action |
With oral dosing, peak effect is seen within 1-2 hours; mortality-reducing antihypertensive effects develop over months and years. Chlorthalidone is extremely long-acting, 50-60 hours, whereas the others are more like 6-12 hrs.
|
| Target receptor |
NCC sodium/chloride cotransporter in the distal convouted tubule |
| Mechanism of action |
By decreasing the reabsoprtion of sodium and chloride in the distal convoluted tubule, thiazides block the reabsorption of up to 5% of the total filtered sodium. This increases the delivery of sodium and chloride to the distal nephron. The increased solutes in the collecting duct lumen decrease the osmotic gradient between the duct and inner medulla, preventing water reabsorption in the collecting duct, resulting in diuresis. |
| Clinical effects |
Hypokalemia, hyponatremia, unexplained vasodilatory antihypertensive effects in the long term |
| Literature reference |
Tamargo et al, 2014 |
| CICM details of understanding | Not specifically listed in the CICM syllabus |
| Mentioned around Deranged Physiology | |
| Related SAQs |
Question 17 from the second paper of 2022 |